Want to see BICX full AI Analyst Report?

BioCorRx (BICX) Price & Analysis

5 Followers

BICX Stock Chart & Stats

$0.32

$0.00(0.00%)

At close: Jan 06 4:00 PM EST

$0.32

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.20 - $1.28

Previous CloseN/A

Volume44.00

Average Volume (3M)824.00

Market Cap

$9.88M

Enterprise Value$8.94M

Total Cash (Recent Filing)$211.91K

Total Debt (Recent Filing)$2.12M

Price to Earnings (P/E)―

Beta0.49

Next Earnings

Aug 17, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.17

Shares Outstanding29,055,548

10 Day Avg. Volume1,315

30 Day Avg. Volume824

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)-0.48

Price to Sales (P/S)6.75

P/FCF Ratio-2.34

Enterprise Value/Market Cap0.90

Enterprise Value/Revenue10.19

Enterprise Value/Gross Profit12.14

Enterprise Value/Ebitda-3.02

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.21

Revenue Forecast (FY)$971.85K

Bulls Say, Bears Say

Bulls Say

Revenue GrowthConsistent and accelerating revenue growth, including a major step-up in 2025, indicates improving product-market fit in substance use disorder services. This expanding top line provides a foundation to scale operations and absorb fixed costs, supporting a path to durable profitability if growth continues.

High Gross MarginA circa-65% gross margin shows the core service and medication-assisted treatment offerings have healthy unit economics. Strong gross margins create room to invest in patient management and clinical services while preserving the potential for operating leverage as revenue scales, aiding long-term margin recovery.

Subsidiary Reorganization Improves ControlThe equity-exchange reorganization consolidates subsidiary ownership under a tax-efficient structure and grants the parent greater strategic flexibility. This reduces near-term cash needs for control, simplifies governance and can enable coordinated operational decisions and potential partnerships over the medium term.

Bears Say

Large Operating And Net LossesVery large operating and net losses relative to the revenue base indicate the company remains far from profitable. Sustained negative earnings erode capital and require repeated external funding, making achieving long-term profitability a material structural challenge absent major cost control or sizeable revenue gains.

Deeply Negative EquityThe large accumulated deficit and negative equity limit access to traditional financing and weaken balance-sheet credibility. This structural capital shortfall increases insolvency risk, pressures refinancing terms, and raises the likelihood of further dilution or restructuring to sustain operations over the medium term.

Persistent Cash BurnConsistent negative operating and free cash flow, coupled with a declining FCF trend, indicate ongoing cash consumption that will require external capital to maintain operations. This structural burn reduces runway for investments and raises the probability of dilutive financing, constraining long-term strategic options.

BioCorRx News

BioCorRx Reorganizes Subsidiary Through Equity Exchange Deal

BioCorRx ( ($BICX) ) has shared an update. On March 26, 2026, BioCorRx Inc. entered into a stock...

3M ago

BICX

BioCorRx Enters Securities Purchase Agreement with Investors

BioCorRx ( ($BICX) ) just unveiled an announcement. On July 29, 2025, BioCorRx Inc. entered into a securities...

11M ago

BICX

BICX FAQ

What was BioCorRx Inc’s price range in the past 12 months?

BioCorRx Inc lowest stock price was $0.20 and its highest was $1.28 in the past 12 months.

What is BioCorRx Inc’s market cap?

BioCorRx Inc’s market cap is $9.88M.

When is BioCorRx Inc’s upcoming earnings report date?

BioCorRx Inc’s upcoming earnings report date is Aug 17, 2026 which is in 45 days.

How were BioCorRx Inc’s earnings last quarter?

BioCorRx Inc released its earnings results on Aug 14, 2025. The company reported -$0.07 earnings per share for the quarter, the consensus estimate of -$0.07 by $0.

Is BioCorRx Inc overvalued?

According to Wall Street analysts BioCorRx Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BioCorRx Inc pay dividends?

BioCorRx Inc does not currently pay dividends.

What is BioCorRx Inc’s EPS estimate?

BioCorRx Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BioCorRx Inc have?

BioCorRx Inc has 29,055,548 shares outstanding.

What happened to BioCorRx Inc’s price movement after its last earnings report?

BioCorRx Inc reported an EPS of -$0.07 in its last earnings report, expectations of -$0.07. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of BioCorRx Inc?

Currently, no hedge funds are holding shares in BICX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

BioCorRx Inc

BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.